EUVIMEDEUVIMED entdecken
Multizentrische Studie

Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study

M C Trojani, D Gensburger, F Bagouet, B Cortet, G Couture, C Marcelli, N Mehsen Cetre, V Breuil, R Chapurlat

Bone · 2023-09 · 174 · 116819

DOI: 10.1016/j.bone.2023.116819 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Bone, 2023-09. Verfasst von M C Trojani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Nice University Hospital, Nice, France; Faculté de Médecine Nice, UMR E-4320 TIRO-MATOs CEA/DRF/Institut Joliot, Universi…. Hauptthemen laut MEDLINE: Fibrous Dysplasia of Bone, Fibrous Dysplasia, Polyostotic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Increased RANKL expression is observed in the bone tissue of fibrous dysplasia of bone/McCune-Albright syndrome (FD/MAS). In one animal model of FD/MAS, the inhibition of RANKL reduced tumor volume. A beneficial effect of denosumab on pain in patients refractory to bisphosphonates has been reported, but without systematic quantification of pain improvement. This work describes the clinical experience of our group on the efficacy on pain of denosumab treatment, along with safety, in FD/MAS patients refractory to bisphosphonates. MATERIALS AND METHODS: We have conducted a retrospective multicenter study in 6 academic rheumatology centers in France. We have collected patients and FD/MAS characteristics, duration of prior exposure to bisphosphonates, denosumab treatment modalities (dosage - administration regimen - number of courses); evolution of pain evaluated by Visual Analogic Scale (VAS). RESULTS: 13 patients were included (10 women and 3 men) 45 years on average, 5 MAS, 4 monostotic and 4 polyostotic forms. The average duration post-diagnosis of FD/MAS was 25 years and the mean duration of prior exposure to bisphosphonates was 4.7 years. Pain could be analyzed in 7 patients, showing a significant improvement from a mean VAS of 7.8 to 2.9 (-4.9 points, p = 0.003). In one patient with fronto-orbital FD/MAS, a 30 % decrease in lesional volume, assessed by MRI, was observed within 6 months of treatment, that was sustained over the following 12 months. Treatment regimens were heterogeneous. No hypercalcemia was observed after treatment cessation and the clinical tolerance was good. DISCUSSION: This study suggests that denosumab reduces pain in patients with DF/MAS refractory to bisphosphonates, and quantifies this improvement for the first time in a multicenter study. In our cohort, no patients who discontinued denosumab developed hypercalcemia and clinical tolerance was overall good. This study also provides encouraging data regarding lesion volume control. Further controlled studies are required to determine the place and modalities of the denosumab treatment of FD/MAS. CONCLUSION: Denosumab significantly decreased pain in FD/MAS refractory to bisphosphonate. This study paves the way for a randomized clinical trial to validate and standardize the prescription of denosumab in FD/MAS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrous Dysplasia of BoneFibrous Dysplasia, PolyostoticFemaleDenosumabDiphosphonatesPainRetrospective StudiesHumansMale

Stichwörter der Autor:innen

DenosumabFibrous dysplasiaPainRANKL

Substanzen

DenosumabDiphosphonates

Autor:innen und Institutionen

  • Department of Rheumatology, Nice University Hospital, Nice, France; Faculté de Médecine Nice, UMR E-4320 TIRO-MATOs CEA/DRF/Institut Joliot, Université Côte d'Azur, CEDEX 2, 06107 Nice, France. Electronic address: troja…
  • INSERM UMR_S 1033, Université Claude Bernard-Lyon 1, Hôpital E Herriot, 69437 Lyon cedex O3, France.
  • Department of Rheumatology, Lille University Hospital and ULR 4490, 59000 Lille, France.
  • Department of Rheumatology, Toulouse University Hospital and University Toulouse III, Toulouse, France.
  • Department of Rheumatology, Caen University Hospital, Caen, France.
  • Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.

Zitieren

APA

Trojani, M. C., Gensburger, D., Bagouet, F., Cortet, B., Couture, G., Marcelli, C., Mehsen Cetre, N., Breuil, V., & Chapurlat, R. (2023). Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study. Bone, 174, 116819. https://doi.org/10.1016/j.bone.2023.116819

Vancouver

Trojani MC, Gensburger D, Bagouet F, Cortet B, Couture G, Marcelli C, et al. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study. Bone. 2023;174:116819. doi:10.1016/j.bone.2023.116819

BibTeX
@article{Trojani2023,
  author = {Trojani, M C and Gensburger, D and Bagouet, F and Cortet, B and Couture, G and Marcelli, C and Mehsen Cetre, N and Breuil, V and Chapurlat, R},
  title = {Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study},
  journal = {Bone},
  year = {2023},
  volume = {174},
  pages = {116819},
  doi = {10.1016/j.bone.2023.116819}
}
Kostenlos starten →